Trevi Therapeutics reports FY2023 net loss $29.1M; cash $83M; trial timelines reaffirmed

Trevi Therapeutics, Inc.

Net loss Q4 2023 $7.8M vs $5.5M in Q4 2022; FY2023 net loss $29.1M vs $29.2M in FY2022.
Cash, cash equivalents and marketable securities $83.0M at year-end 2023; expected runway into 2026.
Phase 2a RIVER trial for RCC topline data expected H2 2024; enrollment continuing across multiple sites.
Phase 2b CORAL trial for chronic cough in IPF topline expected H1 2025; SSRE expected H2 2024.
Human Abuse Potential study over 50% enrolled; topline data expected H2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: net income Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.. Guidance reaffirmed.

Period: quarter and year ended December 31, 2023
Net income: Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-034159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.